Harnessing regulatory t cells for clinical use in transplantation: The end of the beginning

American Journal of Transplantation

Volumn 14, Issue 4, 2014, Pages 750-763

  Juvet, S C ^a   Whatcott, A G ^a   Bushell, A R ^a   Wood, K J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Allograft tolerance; cellular therapy; hematopoietic stem cell transplantation; regulatory T cells; solid organ transplantation

Indexed keywords

ALLOANTIGEN;

CELL THERAPY; CELL TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SOLID ORGAN TRANSPLANTATION; BIOLOGICAL THERAPY; IMMUNOLOGY; PROGNOSIS; TRANSPLANTATION TOLERANCE;

CELL- AND TISSUE-BASED THERAPY; HUMANS; ORGAN TRANSPLANTATION; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84897116999     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12647     Document Type: Review

References (138)

1. Qin S, Cobbold SP, Pope H, et al. " Infectious" transplantation tolerance. Science 1993; 259: 974-977.
2. Hester J, Schiopu A, Nadig SN, Wood KJ., Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 2012; 12: 2008-2016.
3. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809-813.
4. + regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
5. Billingham RE, Brent L, Medawar PB., Actively acquired tolerance of foreign cells. Nature 1953; 172: 603-606.
6. Gershon RK, Kondo K., Infectious immunological tolerance. Immunology 1971; 21: 903-914.
7. Kilshaw PJ, Brent L, Pinto M., Suppressor T-cells in mice made unresponsive to skin allografts. Nature 1975; 255: 489-491.
8. Hall BM, Jelbart ME, Gurley KE, Dorsch SE., Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med 1985; 162: 1683-1694.
9. + suppressor cell and its mechanisms of action. J Exp Med 1990; 171: 141-157.
10. Quigley RL, Wood KJ, Morris PJ., Transfusion induces blood donor-specific suppressor cells. J Immunol 1989; 142: 463-470.
11. Pearson TC, Darby CR, Bushell AR, West LJ, Morris PJ, Wood KJ., The assessment of transplantation tolerance induced by anti-CD4 monoclonal antibody in the murine model. Transplantation 1993; 55: 361-367.
12. Wheelahan J, McKenzie IF., Tolerance induction to murine class II MHC molecules by anti-CD4 antibody. Transplant Proc 1989; 21 (1 Pt 1): 246-247.
13. Herbert J, Roser B., Strategies of monoclonal antibody therapy that induce permanent tolerance of organ transplants. Transplantation 1988; 46: 128S-134S.
14. + T cell regulation during the induction phase of the response. Eur J Immunol 1995; 25: 2643-2649.
15. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
16. + regulatory T cells. Nat Immunol 2003; 4: 330-336.
17. Hori S, Nomura T, Sakaguchi S., Control of regulatory T cell development by the transcription factor FoxP3. Science 2003; 299: 1057-1061.
18. + T regulatory cells. Nat Immunol 2003; 4: 337-342.
19. + regulatory T cells by TGF-beta induction of transcription factor FoxP3. J Exp Med 2003; 198: 1875-1886.
20. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S., Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
21. Taylor PA, Lees CJ, Blazar BR., The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
22. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
23. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080-1086.
24. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G., Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-1310.
25. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH., Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-1294.
26. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
27. - T regulatory cells. Clin Immunol 2009; 133: 22-26.
28. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
29. Marek-Trzonkowska N, Mysliwec M, Siebert J, Trzonkowski P., Clinical application of regulatory T cells in type 1 diabetes. Pediatr diabetes 2013; 14: 322-332.
30. Geissler EK., The ONE study compares cell therapy products in organ transplantation: Introduction to a review series on suppressive monocyte-derived cells. Transplant Res 2012; 1: 11-13.
31. Wood KJ, Bushell A, Hester J., Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417-430.
32. Vignali DA, Collison LW, Workman CJ., How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532.
33. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-296.
34. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F., An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004.
35. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008; 28: 546-558.
36. Read S, Malmstrom V, Powrie F., Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302.
37. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-310.
38. + regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009; 206: 421-434.
39. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789-3796.
40. + Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232.
41. + regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183: 7602-7610.
42. + regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol 2009; 123: 1287-1296.e2.
43. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
44. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311-323.
45. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S., Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-142.
46. + regulatory T cells without enhancing effector T-cell function. Am J Transplant 2007; 7: 759-768.
47. Sonawane SB, Kim JI, Lee MK, et al. GITR blockade facilitates Treg mediated allograft survival. Transplantation 2009; 88: 1169-1177.
48. Cobbold SP, Adams E, Farquhar CA, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA 2009; 106: 12055-12060.
49. Sucher R, Fischler K, Oberhuber R, et al. IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. J Immunol 2012; 188: 37-46.
50. + regulatory T cells is essential for preventing experimental graft-versus-host disease. J Immunol 2012; 189: 2890-2896.
51. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ., IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005; 201: 1925-1935.
52. Wei B, Baker S, Wieckiewicz J, Wood KJ., IFN-gamma triggered STAT1-PKB/AKT signalling pathway influences the function of alloantigen reactive regulatory T cells. Am J Transplant 2010; 10: 69-80.
53. Brok HP, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM., Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-6459.
54. Wood KJ, Feng G, Wei B, Sawitzki B, Bushell AR., Interferon gamma: Friend or foe ? Transplantation 2007; 84: S4-S5.
55. + T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptotic signals. J Immunol 2007; 179: 939-949.
56. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK., Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196: 999-1005.
57. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997-1002.
58. Goodman WA, Cooper KD, McCormick TS., Regulation generation: The suppressive functions of human regulatory T cells. Crit Rev Immunol 2012; 32: 65-79.
59. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA., Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6666.
60. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008; 205: 2221-2234.
61. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ., Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589-601.
62. + regulatory T cells: Independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immunol 2007; 179: 3578-3587.
63. + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13 (15 Pt 1): 4345-4354.
64. Macedo C, Orkis EA, Popescu I, et al. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009; 9: 2057-2066.
65. Yang J, Brook MO, Carvalho-Gaspar M, et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci USA 2007; 104: 19954-19959.
66. Afzali B, Mitchell PJ, Scotta C, et al. Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells. Am J Transplant 2011; 11: 1734-1742.
67. Dons EM, Raimondi G, Cooper DK, Thomson AW., Non-human primate regulatory T cells: Current biology and implications for transplantation. Transplantation 2010; 90: 811-816.
68. Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7: 83-92.
69. + T cells and dendritic cells in vivo. J Exp Med 2006; 203: 505-511.
70. Carvalho-Gaspar M, Jones ND, Luo S, Martin L, Brook MO, Wood KJ., Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol 2008; 180: 6640-6648.
71. + regulatory T cells in vivo. J Exp Med 2003; 198: 249-258.
72. + regulatory T cells: Evidence for in vivo inhibition of effector cell proliferation. J Immunol 2004; 172: 6539-6544.
73. + regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109: 827-835.
74. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004; 104: 3804-3812.
75. Rosengard BR, Kortz EO, Guzzetta PC, et al. Transplantation in miniature swine: Analysis of graft-infiltrating lymphocytes provides evidence for local suppression. Hum Immunol 1990; 28: 153-158.
76. Graca L, Cobbold SP, Waldmann H., Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641-1646.
77. Zhang N, Schroppel B, Lal G, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009; 30: 458-469.
78. Tang Q, Lee K., Regulatory T-cell therapy for transplantation: How many cells do we need ? Curr Opin Organ Transplant 2012; 17: 349-354.
79. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H., Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002; 168: 5558-5565.
80. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 2011; 3: 83ra41.
81. + cells in the recipient. Int Immunol 2006; 18: 279-289.
82. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M., Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004; 104: 895-903.
83. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant 2011; 11: 1148-1157.
84. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G., Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3: 83ra42.
85. Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C., Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood 2011; 118: 5671-5680.
86. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013; 13: 3010-3020.
87. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008; 181: 2855-2868.
88. + regulatory T cells by retinoic acid. J Immunol 2009; 183: 4119-4126.
89. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL., Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE 2011; 6: e15868.
90. + regulatory T cells. Blood 2005; 105: 4743-4748.
91. Levings MK, Sangregorio R, Roncarolo MG., Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-1302.
92. Carlson MJ, Fulton LM, Coghill JM, et al. L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation. Am J Transplant 2010; 10: 2596-2603.
93. + T cells. Eur J Immunol 2007; 37: 129-138.
94. + Treg cells. J Exp Med 2006; 203: 1701-1711.
95. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
96. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
97. Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990; 336: 850-854.
98. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K., Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90: 1321-1327.
99. Wu DC, Hester J, Nadig SN, et al. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation 2013; 96: 707-716.
100. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the FoxP3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
101. Veerapathran A, Pidala J, Beato F, et al. Human regulatory T cells against minor histocompatibility antigens: Ex vivo expansion for prevention of graft-versus-host disease. Blood 2013; 122: 2251-2261.
102. Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ., Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8: 257-260.
103. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347.
104. MacMillan ML, Weisdorf DJ, Brunstein CG, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: Analysis of risk factors. Blood 2009; 113: 2410-2415.
105. + regulatory T cells. J Immunol Methods 2007; 327: 53-62.
106. Figueroa-Tentori D, Querol S, Dodi IA, Madrigal A, Duggleby R., High purity and yield of natural Tregs from cord blood using a single step selection method. J Immunol Methods 2008; 339: 228-235.
107. Milward K, Issa F, Hester J, Figueroa-Tentori D, Madrigal A, Wood KJ., Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation 2013; 95: 85-93.
108. + CD25 high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108: 4260-4267.
109. + T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
110. + regulatory T cells allows for their purification from expansion cultures. Blood 2009; 113: 5125-5133.
111. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
112. Yamashita K, Zaitsu M, Nagatsu A, et al. A clinical trial of regulatory T cell-based immunotherapy for tolerance induction in living donor liver transplantation. Vienna: European Society for Organ Transplantation, 2013.
113. Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J., Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009; 39: 948-955.
114. Zhou XY, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor FoxP3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10: U1000-U1104.
115. Miyao T, Floess S, Setoguchi R, et al. Plasticity of FoxP3(+) T cells reflects promiscuous FoxP3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012; 36: 262-275.
116. - precursors. Am J Transplant 2004; 4: 1614-1627.
117. Zhang P, Tey SK, Koyama M, et al. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J Immunol 2013; 191: 5291-5303.
118. Beres A, Komorowski R, Mihara M, Drobyski WR., Instability of FoxP3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res 2011; 17: 3969-3983.
119. Sharif-Paghaleh E, Sunassee K, Tavare R, et al. In vivo SPECT reporter gene imaging of regulatory T cells. PLoS ONE 2011; 6: e25857.
120. + T cells by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Anal Chem 2013; 85: 10627-10634.
121. Kahan BD, Camardo JS., Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 1181-1193.
122. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399.
123. + T regulatory cell subpopulations. Haematologica 2013; 98: 1291-1299.
124. + regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS ONE 2012; 7: e35572.
125. + cells during treatment of human lung transplant recipients with rapamycin. Transpl Int 2010; 23: 266-276.
126. Raimondi G, Sumpter TL, Matta BM, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol 2010; 184: 624-636.
127. Hester J, Mills N, Shankar S, Carvalho-Gaspar M, Friend P, Wood KJ., Th17 cells in alemtuzumab-treated patients: The effect of long-term maintenance immunosuppressive therapy. Transplantation 2011; 91: 744-750.
128. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007-1018.
129. + regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550-557.
130. Presser D, Sester U, Mohrbach J, Janssen M, Kohler H, Sester M., Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens. Kidney Int 2009; 76: 557-566.
131. Siepert A, Ahrlich S, Vogt K, et al. Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. Am J Transplant 2012; 12: 2384-2394.
132. Stanojlovic S, Schlickeiser S, Appelt C, et al. Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1447-1456.
133. Miroux C, Morales O, Ouaguia L, et al. Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil. Transplant Proc 2012; 44: 2834-2839.
134. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702.
135. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008; 8: 1529-1536.
136. Ho ET, Wong G, Craig JC, Chapman JR., Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: A systematic review. Transplantation 2013; 95: 1120-1128.
137. Cravedi P, Heeger PS., Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012; 17: 26-32.
138. Lee CM, Wu YW, Jui HY, et al. Intravascular ultrasound correlates with coronary flow reserve and predicts the survival in angiographically normal cardiac transplant recipients. Cardiology 2008; 109: 93-98.